Healthcare Industry News: Oncotype DX
News Release - June 1, 2007
Genomic Health Announces Exclusive Distribution Agreement for Oncotype DX Breast Cancer Assay in United KingdomREDWOOD CITY, Calif., June 1 (HSMN NewsFeed) -- Genomic Health, Inc. (Nasdaq: GHDX ) today announced that the company signed an exclusive agreement with Medical Solutions plc (LSE: MLS ), a healthcare and diagnostics business specializing in diagnostic pathology and cytology services and products, to distribute the company's Oncotype DX breast cancer assay in the United Kingdom.
"We view this U.K. partnership as an important milestone in making our Oncotype DX breast cancer assay more widely available," said Chu Chang, Genomic Health's Vice President of Business Development. "We plan to continue to realize opportunities to broaden access to our test to patients outside of the United States, who may benefit from the individualized information Oncotype DX results provide."
Oncotype DX is currently offered for sale in Israel under a testing and services agreement with Teva Pharmaceutical Industries Ltd., and in Japan under an agreement with SRL, Inc. Patient tumor samples from these and numerous other countries around the world are analyzed in Genomic Health's reference laboratory in Redwood City, California.
About Genomic Health
Genomic Health, Inc. (Nasdaq: GHDX ) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test, Oncotype DX(TM), which has been shown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in a large portion of early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com.
About Medical Solutions plc (LSE: MLS )
Medical Solutions is a fully listed UK based diagnostics and healthcare business specialising in the provision of pathology and cytology services and products to the healthcare, pharmaceutical and biotechnology sectors. It has internationally recognised expertise in histopathology with advanced technology in image analysis, high throughput quantitative protein expression and biomarker determination. For more information about Medical Solutions please visit http://www.medical-solutions.co.uk.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to greater accessibility to our Oncotype DX test as a result of the agreement with Medical Solutions plc and our plans to continue to realize additional opportunities to broaden access to our Oncotype DX test. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to: our ability to increase usage of our tests; the risk that we may not obtain or maintain sufficient levels of reimbursement for our existing tests and any future tests we may develop; the risks and uncertainties associated with the regulation of our test by FDA; our ability to obtain capital when needed; our history of operating losses; the results of clinical studies and the other risks set forth in our filings with the Securities and Exchange Commission, including the risks set forth in our Quarterly Report on Form 10-Q for the three-month period ended March 31, 2007. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.
NOTE: Genomic Health, the Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.
Source: Genomic Health
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.